New algorithm more accurately predicts life expectancy after heart failure
(UCLA Samueli School of Engineering) A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant.
Abbott (NYSE:ABT) yesterday presented data from a new trial of its HeartMate 3 left ventricular assist device, touting a reduced rate of strokes, pump-related blood clots and bleeding episodes at two years as compared with the previous generation HeartMate II. Data in the trial was presented at the American College of Cardiology’s 68th Annual Scientific Session 2019 in New Orleans and published simultaneously in the New England Journal of Medicine, the Chicago-area medical device company said. Abbott touted its HeartMate 3 as the first implantable mechanical pump using fully magnetic levitation technology, makin...
Across the nation, a shortage of available organ donors significantly delays heart failure patients ’ time to transplant. The median national waitlist time is 9.3 months 1 with a roughly 8% waitlist mortality. However, despite this costly delay, only 36% of 82,053 potential donor hearts were transplanted between 1995 and 2010. 2
END-STAGE HEART FAILURE (HF) results from a myriad of etiologies and represents a major financial and healthcare burden.1 Since 1983, nearly 150,000 pediatric and adult heart transplants have been reported to the International Society for Heart and Lung Transplantation (ISHLT) Registry, with medical advancements in perioperative care resulting in improved patient outcomes over time.2 This paper aims to assess outcomes within the field of heart transplantation. The authors will focus on historical context, current demographics, indications, and contraindications for transplantation.
Right-sided heart failure develops in lung transplantation candidates on prolonged peripheral extracorporeal membrane oxygenation support and is a major determinant of mortality. The use of central venoarterial extracorporeal membrane oxygenation for bridging of right-sided heart failure to lung transplantation was evaluated.
Systolic heart failure (HF) is a progressive disease characterized by adverse remodeling from ischemia (ischemic cardiomyopathy, ICM) or a multitude of other causes termed non-ischemic cardiomyopathy (NICM). To accurately characterize the myocardial transcriptome in advanced HF using RNA-sequencing (RNAseq) and identify gene signatures that predict HF phenotypes.
Current data regarding early and late right heart failure (RHF) post-LVAD is confounded by small populations and variable definitions of RHF. In 2014, a new INTERMACS (IM) definition of RHF was introduced. Based on this contemporary definition, we sought to investigate the epidemiology and natural history of RHF after LVAD.
LImited mechanical support options exist for patients in biventricular heart failure. Post-transplant outcomes in those bridged with BiVAD HVADs and Total Artificial Heart (TAH) have not been well described. We sought to examine post heart transplant outcomes of this cohort in a national registry.
Leg muscle strength (LMS) could be an index of frailty in patients with heart failure. However, its prognostic value in patients with acute decompensated heart failure (ADHF) is not well investigated. We hypothesized that impaired LMS was independently associated with poor clinical outcome in patients with ADHF.
Multiorgan Dysfunction Syndrome (MOD) contributes to adverse outcomes in advanced heart failure (AdHF) patients after mechanical circulatory support (MCS) implantation and is associated with aberrant Peripheral Blood Mononuclear Cells (PBMC) activity. We hypothesize that a subset of previously reported 12 preoperative differentially expressed genes (DEGs) correlating with both, Functional Recovery Potential (FRP) (28 genes) and One Year Survival (1YS) (105 genes) [Bondar 2017], could directly predict FRP-related 1YS after MCS surgery.
Cardiac resynchronization therapy (CRT) improves quality of life and survival in patients with heart failure, but it has not been rigorously investigated in LVAD patients. Furthermore, the effects of different pacing strategies on hemodynamics in LVAD recipients is unknown.